The Board of the company currently consists of one executive member and six non-executive members, each of whom is considered by the Board to be independent in character and judgment. The Board performs regular reviews of its composition as to background, function and experience, in order to ensure diversity and to balance valuable experience of Idorsia’s business with fresh perspectives.
Board of Directors
Date of birth: 6 May, 1956
Nationality: FrenchShow more
Education: Université de Paris (Paris 7).
Professional background: Former Chairman of the Board of Cellartis AB, 2012–2014; Executive Vice-President, Chief Operating Officer of Cellectis Group, 2013–2018; CEO of Cellectis Therapeutics, 2012–2013, and CEO of Ectycell, 2012–2014; Managing Director, Head of Global Pharma operations at Pierre Fabre SA, 2010–2011. Various management and EU regional management roles as well as senior corporate functions at Wyeth Pharmaceuticals.
Other activities and functions: Member of the Board of Directors of three listed companies, Affimed, Asarina Pharma and Lysogene, and of two unlisted companies, Epsilen Bio (Chairman) and Vaximm.Show less
Date of birth: 3 April, 1955
Nationality: Swiss and FrenchShow more
Education: Medical degree in France; further training in pharmacology and physiology at the University of Montreal, Canada, and the University of California, San Francisco, US.
Professional background: Practicing cardiologist, 1980–1985. Head of Drug Discovery Group in the Cardiovascular Department of F. Hoffmann-La Roche Ltd, 1985–1997. Founder of Actelion in 1997 and CEO 2000–2017.
Other activities and functions: None.Show less
Date of birth: 22 February, 1959
Nationality: GermanShow more
Education: Business degrees from the European Business School and Harvard Business School (Advanced Management Program).
Professional background: Chief Executive Officer of uniQure N.V., 2009–2016, President and Chief Executive Officer of Evotec AG, 1997–2008, and former Chairman of the Board of Directors of Molecular Partners, 2007–2018.
Other activities and functions: CEO of the listed company HOOKIPA Pharma Inc. and Chairman of the Board of Directors of the unlisted company Genespire S.r.l.Show less
Date of birth: February 18, 1951
Nationality: FrenchShow more
Education: Graduate of the École des hautes études commerciales (HEC Paris) and the École nationale d’administration (ENA).
Professional background: Auditor at the French Ministry of Finance, 1976–1980, Advisor to the Minister of Defense, 1980–1981, GM of Pharmuka, 1982–1986, Chief of Staff of the Minister of Industry and Telecommunications, 1986–1988, CEO of Rhone Poulenc Fibers and Polymers, 1988–1993, Chairman & CEO of Rhône Poulenc Rorer & Rhône-Poulenc Santé, 1993–1999, Chairman & CEO of ViroPharma, 2000–2008; Chairman & CEO and GM of Eutelsat, 2009–2017.
Other activities and functions: Member and Chairman of the Board of Directors of three listed companies, DBV Technologies, Faurecia, and Pharnext.Show less
Date of birth: February 26, 1957
Nationality: SwissShow more
Education: Doctorate in law from the University of Zurich, Master of Laws in Business & Taxation from the McGeorge School of Law, California, and further education at Harvard Business School. Attorney-at-Law (since 1986) admitted to practice in Switzerland.
Professional background: Group General Counsel and member of the Executive Committee of Novartis, 2011–2018, Partner, 1992–2011, and Senior Partner and Executive Chairman of Bär & Karrer, 2003–2011. Board member in several listed and non-listed companies.
Other activities and functions: Member of the Board of Directors of one listed company, Geberit AG, and three non-listed companies, Globalance Bank AG (Chairman), Hyos Investment Holding AG and Swiss Fintech AG. Foundation Board Member of the Law and Economics Foundation St. Gallen (University of St. Gallen) and of the UZH Foundation (University of Zurich).Show less
Date of birth: January 24, 1965
Nationality: AmericanShow more
Education: Master of Laws degrees from Cornell University & New York University and member of the New York State Bar.
Professional background: Chief Financial Officer and Chief Business Officer at Sarepta Therapeutics, 2012–2020, SVP at Celgene, 2006–2012. Held senior roles in business development & tax at Pfizer and began his career at Ernst & Young.
Other activities and functions: Member of the Board of Directors of two listed companies, Aeglea BioTherapeutics (Chairman) and Flexion Therapeutics and Board Member of the unlisted company Epirium Bio; President, COO and CFO of the unlisted company National Resilience, Inc.Show less
Date of birth: 15 October, 1963
Nationality: FrenchShow more
Education: MBA, Ecole Supérieure de Commerce de Paris.
Professional background: Held various executive positions such as Head of Finance and Control NBE at Nestlé, 2014–2017, Group CFO of Galderma, 2010–2014, Global Division CFO at Novartis OTC, 2006–2010, Global Pharma Business unit CFO and EMEA CFO at Wyeth, 1997–2006.
Other activities and functions: Member of the Board of Directors of three listed companies, DBV Technologies, UCB and Voluntis SA, and two unlisted companies, Novo Holdings and Yellow Tangerine SA.Show less
Elections and Terms of Office
Under Articles 13 and 16 of the Articles of Association, the 3–9 members of the Board of Directors are elected individually by the General Meeting of the Shareholders for a term of office corresponding to the legally permitted maximum term of one year. One year of office is understood to be the period from one ordinary Meeting of the Shareholders to the next ordinary Meeting of the Shareholders.
Time of First Election and Remaining Term of Office
|Date of AGM of first election||Date of AGM of end of term|
|Michel de Rosen||No||2020||2021|
|Felix R. Ehrat||No||2020||2021|